NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with ...

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – NEW HAVEN, Conn., February 11, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage ...

The first participant has received a dose in a study that will examine the pharmacokinetics (PK) and safety of the therapy in pregnant women at risk for HPA-1a alloimmunization, which can cause FNAIT.

The single-arm, dose confirmation trial aims to assess RLYB212's pharmacokinetics (PK) and safety in pregnant women who are at a higher risk for human platelet antigen (HPA) 1a alloimmunisation ...